$VTRS

Viatris (VTRS) received Japanese approval for WAKIX, expanding its market. The stock is up 36% YTD and 77% over 1 year, closing at $16.95. Analysts estimate a fair value of $18.50, suggesting an 8% undervaluation. The company expects long-term growth from aging populations and chronic disease prevalence, but faces risks from generic price pressure and integration costs.

Piper Sandler raised its price target for Viatris (VTRS) to $13.00, citing growth in its estradiol patch business and upcoming Phase III readouts. The stock is up 80% over the past year, trading at $16.65. Viatris reported better-than-expected Q2 2026 earnings and revenue, raising its full-year guidance. Piper Sandler maintains a Neutral rating, noting risks tied to biosimilars and clinical trial outcomes.

Viatris Inc. (VTRS) received approval in Japan for WAKIX® (pitolisant) to treat narcolepsy and excessive daytime sleepiness in obstructive sleep apnea syndrome. This is the first histamine H3 receptor antagonist/inverse agonist approved for these conditions in Japan, addressing a high unmet medical need. The approval was supported by clinical trial data.

Piper Sandler raised its price target for Viatris to $13 from $12 while maintaining a neutral rating. The stock has a 5-day change of 16.65 USD, a 1st Jan change of -0.06%, and a 1-year change of +33.73%.

Viatris Korea appointed Kim Sun-A to lead its new Japan-Korea cluster, overseeing strategy and collaboration between the regions. She retains her role as president of Viatris Japan. The move aims to boost cooperation between the countries' operations. Bill Schuster remains president of Viatris Korea, managing its local operations.

A phase 3 trial of 0.75% phentolamine eye drops by Opus Genetics and Viatris showed 21% of adults with night vision issues improved on a dim-light eye chart after 15 days, compared to 3% on placebo. The drop, not yet FDA-approved for night vision, aims to reduce glare and halos. Results were published in the American Journal of Ophthalmology. A confirmatory trial is expected in 2026.

Viatris (VTRS) filed an amended Schedule 13G/A, disclosing that FMR LLC and Abigail P. Johnson collectively own 11.0% of its shares (126,764,446.45 shares) as of August 31, 2026. FMR LLC holds sole voting power over 113,359,609.44 shares and sole dispositive power over all 126,764,446.45 shares, while Johnson has sole dispositive power but no voting rights.

FDA is working with six unnamed manufacturers to increase supply of menopause patches due to surging demand. Reuters reports women are facing challenges obtaining them. Companies like Amneal, Sandoz, Noven, Bayer, Zydus, and Viatris sell these patches. Bayer expects temporary supply constraints until early 2027, while Viatris is adding production lines and seeking partners to boost supply.

The FDA is collaborating with six manufacturers to boost estradiol patch supply amid increased demand and access issues. Companies like Bayer, Sandoz, and Viatris are expanding production. Bayer expects temporary supply constraints until early 2027. The FDA is monitoring supply and assisting manufacturers.

Viatris (VTRS) reported Q2 2026 with higher sales and revenue, completed a $1.15B share buyback, and raised 2026 revenue guidance to $14.75B, despite a net loss. The company affirmed a $0.12 quarterly dividend. Management's confidence is noted, but pricing pressure and regulatory risks remain concerns.